Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Pyridoxamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.93 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | HPGD | P15428 | 2/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | PDXK | O00764 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.50 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.49 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridoxamine SCHEMBL30408 | 0.96 | LMNA (1.00) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| Pyridoxamine SCHEMBL7749395 | 0.95 | LMNA (0.96) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| Pyridoxamine SCHEMBL48103 | 0.95 | LMNA (0.96) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| Pyridoxamine SCHEMBL561421 | 0.95 | LMNA (0.96) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| Pyridoxamine SCHEMBL9291549 | 0.93 | LMNA (0.93) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| Pyridoxamine SCHEMBL3555546 | 0.93 | LMNA (0.93) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| Pyridoxamine SCHEMBL11424618 | 0.92 | LMNA (0.90) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| Pyridoxamine SCHEMBL43833 | 0.89 | LMNA (0.84) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| Pyridoxine SCHEMBL1092163 | 0.87 | HPGD (0.92) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| Pyridoxamine SCHEMBL8904115 | 0.87 | LMNA (0.82) | LMNAKDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108624549-B | CHO DG44 culture medium and application thereof | 上海奥浦迈生物科技有限公司 | 2020-11-20 | — | — | CN | disclosed |
| CN-108624549-A | A kind of CHO DG44 culture mediums and its application | 上海奥浦迈生物科技有限公司 | 2018-10-09 | — | — | CN | disclosed |
| US-20080096923-A1 | Methods For Diagnosing And Treating Diabetic Microvascular Complications | ELI LILLY AND COMPANY | 2008-04-24 | — | — | US | disclosed |
| WO-2006019851-A1 | METHODS FOR DIAGNOSING AND TREATING DIABETIC MICROVASCULAR COMPLICATIONS | ELI LILLY AND COMPANY (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096923-A1 | Methods For Diagnosing And Treating Diabetic Microvascular Complications | FLT4, TEK, MAP3K13 | LMNA 3341/4885KDM4E 1220/4885ALDH1A1 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.